SIRT6 is essential for these pharmacological activities of GB1a described above, and GB1a could act as an agonist of SIRT6 to delay the pathological progression of NAFLD. The gene discussed is SIRT6; the disease is metabolic dysfunction-associated steatotic liver disease.